AUTHORS
Ryanne June Mulligan, BS, Ya Huang, PhD2, Xueyuan Cao, PhD3, Jeffrey Rubnitz, MD, PhD4, Hiroto Inaba, MD. PHD5, Raul Ribeiro, MD6, Jeffery M. Klco, Member; Director, Division of Hematopathology and Molecular Pathology7, Tanja Gruber, MD8, Junmin Peng, PhD9, Stanley Pounds, PhD10, Jatinder K Lamba, PhD11
AFFILIATIONS
1 University of Florida, Gainesville, Florida, United States
2 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
3 University of Tennessee Health Science Center, Memphis, Tennessee, United States
4 Ascentage Pharma, Rockford, Maryland, United States
5 St. Jude Children’s Research Hospital, Memphis, Tennessee, United States
6 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
7 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
8 Stanford University School of Medicine, Stanford, California, United States
9 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
10 St. Jude Children's Research Hospital, Memphis, Tennessee, United States
11 University of Florida, Gainesville, Florida, United States
ABSTRACT
Background: Lower genome-wide DNA methylation burden has been associated with improved survival in pediatric acute myeloid leukemia (AML). Coupled with the growing interest in less intensive treatment strategies for younger patients, hypomethylating agents (HMAs) are increasingly being incorporated into frontline therapy. Although HMA-induced changes in DNA methylation and gene expression have been described, their effects on the in vivo proteomic landscape remain poorly characterized.
Methods: We investigated global proteomic changes in pediatric AML patients enrolled on the AML16 clinical trial (NCT03164057), in which newly diagnosed patients were randomized to receive 5-day priming with either azacitidine (AZA) or decitabine (DAC) before each chemotherapy course. Global proteomic profiling was performed on 39 paired specimens collected at diagnosis and after 5 days of in vivo HMA exposure (DAC, n=25; AZA, n=14). Proteins were quantified using 18-plex tandem mass tag (TMT)-based mass spectrometry (MS) with an internal reference standard and analyzed using the JUMP proteomics pipeline. Following normalization and batch correction, paired t-tests were performed to identify differentially expressed proteins in the combined cohort and within each treatment arm separately. Gene set enrichment analysis (GSEA) was performed using KEGG pathways.
Results: 8,346 proteins were quantified across all samples. Comparison of paired pre- and post-HMA specimens identified 30 differentially expressed proteins in the combined cohort, 29 in the AZA, and 54 in the DAC arm (p<0.01). Consistent with the expected pharmacologic mechanism of HMAs, all three DNA methyltransferases (DNMT1, DNMT3A, and DNMT3B) were significantly downregulated following treatment (all p<0.001), with DNMT3A reduced by both AZA and DAC and DNMT1 and DNMT3B inhibited significantly by DAC priming only.
Despite both being hypomethylating agents, AZA and DAC induced distinct proteomic remodeling. AZA altered 29 proteins, whereas DAC altered 54 proteins (p<0.01) with CDCA7L, an oncogenic regulator implicated in cell proliferation, and dihydrofolate reductase (DHFR), the molecular target of methotrexate, among the most highly upregulated proteins following both treatments. More broadly, AZA and DAC generated largely non-overlapping protein signatures affecting pathways involved in chromatin regulation, RNA processing, proliferation, and cellular metabolism.
Pathway analysis further highlighted divergent biological effects of the two HMAs. AZA upregulated spliceosome, ribosome biogenesis, and folate biosynthesis pathways while suppressing proteasome, Toll-like receptor, and mTOR signaling. In contrast, DAC priming upregulated cadherin signaling, MAPK signaling, and regulation of the actin cytoskeleton while downregulating the spliceosome pathway. Most notably, the spliceosome pathway was regulated in opposite directions following AZA and DAC treatment, suggesting fundamentally different effects on RNA splicing despite their shared epigenetic mechanism of action. These findings will be further investigated through splice variant analysis using matched transcriptomic data.
Conclusions: This study provides, to our knowledge, the first comprehensive characterization of global proteomic remodeling following in vivo HMA priming in paired pediatric AML specimens and the first direct comparison of azacitidine- and decitabine-induced proteomic responses within a prospective clinical trial. Beyond confirming expected DNMT depletion, our findings demonstrate that AZA and DAC elicit distinct protein and pathway signatures, with opposing regulation of the spliceosome pathway emerging as a prominent differentiating feature. These results provide new biological insight into the differential activity of HMAs and establish a foundation for biomarker discovery, rational combination therapies, and optimization of HMA-based treatment strategies in pediatric AML. Ongoing studies are evaluating cytogenetic subtype-specific proteomic responses and associations between HMA-induced proteomic alterations and clinical outcomes.
DISCLOSURES
Ryanne June Mulligan, BS: No relevant conflicts of interest to declare.